The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis
European Respiratory Journal · 2024
DOI: 10.1183/13993003.01705-2023 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Lee Hatter und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute of New Zealand, Wellington, New Zealand lee.hatter@mrinz.ac.nz. Hauptthemen laut MEDLINE: Asthma, Budesonide, Carbon Footprint, Formoterol Fumarate. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Introduction
The use of pressurised metered-dose inhalers (pMDIs) and asthma exacerbations necessitating healthcare reviews contribute substantially to the global carbon footprint of healthcare. It is possible that a reduction in carbon footprint could be achieved by switching patients with mild asthma from salbutamol pMDI reliever-based therapy to inhaled corticosteroid-formoterol dry powder inhaler (DPI) reliever therapy, as recommended by the Global Initiative for Asthma.
Methods
This post hoc analysis included all 668 adult participants in the Novel START trial, who were randomised 1:1:1 to treatment with as-needed budesonide/formoterol DPI, as-needed salbutamol pMDI or maintenance budesonide DPI plus as-needed salbutamol pMDI. The primary outcome was carbon footprint of asthma management, expressed as kilograms of carbon dioxide equivalent emissions (kgCO 2 e) per person-year. Secondary outcomes explored the effect of baseline symptom control and adherence (maintenance budesonide DPI arm only) on carbon footprint.
Results
As-needed budesonide/formoterol DPI was associated with 95.8% and 93.6% lower carbon footprint compared with as-needed salbutamol pMDI (least-squares mean 1.1 versus 26.2 kgCO 2 e; difference −25.0, 95% CI −29.7 to −20.4; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Research Institute of New Zealand, Wellington, New Zealand lee.hatter@mrinz.ac.nz.
- School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
- Medical Research Institute of New Zealand, Wellington, New Zealand.
- Nuffield Department of Clinical Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK.
- Woolcock Institute of Medical Research and Macquarie University, Sydney, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
ORCID-Profile: Lee Hatter, Pepa Bruce, Helen K Reddel, Robert J Hancox, Alberto Papi, Richard Beasley
Zitieren
APA
Hatter, L., Holliday, M., Eathorne, A., Bruce, P., Pavord, I. D., Reddel, H. K., Hancox, R. J., Papi, A., Weatherall, M., & Beasley, R. (2024). The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. European Respiratory Journal. https://doi.org/10.1183/13993003.01705-2023
Vancouver
Hatter L, Holliday M, Eathorne A, Bruce P, Pavord ID, Reddel HK, et al. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. European Respiratory Journal. 2024. doi:10.1183/13993003.01705-2023
BibTeX
@article{Hatter2024,
author = {Hatter, Lee and Holliday, Mark and Eathorne, Allie and Bruce, Pepa and Pavord, Ian D and Reddel, Helen K and Hancox, Robert J and Papi, Alberto and Weatherall, Mark and Beasley, Richard},
title = {The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.01705-2023}
}
EUVIMED